We recently learned that home DNA-testing company 23andMe will be going public through a merger with special purpose acquisition company (SPAC) VG Acquisition Corp (NYSE: VGAC) . In this Fool Live video clip, recorded on March 15 , Fool.com contributor Matt Frankel, CFP, explains to Industry Focus host Jason Moser why he owns shares of this high-potential genetics company in his personal stock portfolio, specifically in the context of their pharmaceutical development potential.
For further details see:
Here's Why I Bought Shares of This Genetics Company